Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Identification of fluorinated (R)-(-)-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor.

Xu Y, Sromek AW, Neumeyer JL.

Bioorg Med Chem Lett. 2019 Jan 15;29(2):230-233. doi: 10.1016/j.bmcl.2018.11.050. Epub 2018 Nov 23.

PMID:
30545651
2.

New Dopamine D2 Receptor Agonist, [3H]MCL-536, for Detecting Dopamine D2high Receptors in Vivo.

Subburaju S, Sromek AW, Seeman P, Neumeyer JL.

ACS Chem Neurosci. 2018 Jun 20;9(6):1283-1289. doi: 10.1021/acschemneuro.8b00096. Epub 2018 Apr 16.

PMID:
29641175
3.

Convenient synthesis of 18F-radiolabeled R-(-)-N-n-propyl-2-(3-fluoropropanoxy-11-hydroxynoraporphine.

Sromek AW, Zhang S, Akurathi V, Packard AB, Li W, Alagille D, Morley TJ, Baldwin R, Tamagnan G, Neumeyer JL.

J Labelled Comp Radiopharm. 2014 Dec;57(14):725-9. doi: 10.1002/jlcr.3246. Epub 2014 Nov 17.

4.

Pharmacological characterization and therapeutic potential for the treatment of opioid abuse with ATPM-ET, an N-ethyl substituted aminothiazolomorphinan with κ agonist and μ agonist/antagonist activity.

Sun JF, Wang YH, Chai JR, Li FY, Hang A, Lu G, Tao YM, Cheng Y, Chi ZQ, Neumeyer JL, Zhang A, Liu JG, Wang YJ.

Eur J Pharmacol. 2014 Oct 5;740:455-63. doi: 10.1016/j.ejphar.2014.06.045. Epub 2014 Jul 3.

PMID:
24998879
5.

(18)F-MCL-524, an (18)F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study.

Finnema SJ, Stepanov V, Nakao R, Sromek AW, Zhang T, Neumeyer JL, George SR, Seeman P, Stabin MG, Jonsson C, Farde L, Halldin C.

J Nucl Med. 2014 Jul;55(7):1164-70. doi: 10.2967/jnumed.113.133876. Epub 2014 May 1.

6.

Preliminary pharmacological evaluation of enantiomeric morphinans.

Sromek AW, Provencher BA, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL.

ACS Chem Neurosci. 2014 Feb 19;5(2):93-9. doi: 10.1021/cn400205z. Epub 2014 Jan 8.

7.

Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.

Provencher BA, Sromek AW, Li W, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL.

J Med Chem. 2013 Nov 14;56(21):8872-8. doi: 10.1021/jm401290y. Epub 2013 Oct 29.

8.

Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.

Ye N, Neumeyer JL, Baldessarini RJ, Zhen X, Zhang A.

Chem Rev. 2013 May 8;113(5):PR123-78. doi: 10.1021/cr300113a. Epub 2013 Mar 7. Review. No abstract available.

PMID:
23464812
9.

Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.

Neumeyer JL, Zhang B, Zhang T, Sromek AW, Knapp BI, Cohen DJ, Bidlack JM.

J Med Chem. 2012 Apr 26;55(8):3878-90. doi: 10.1021/jm3001086. Epub 2012 Apr 4.

10.

A tribute to Joseph G. Cannon, 1926-2011.

Neumeyer JL.

J Med Chem. 2012 Feb 23;55(4):1423. doi: 10.1021/jm300081m. Epub 2012 Feb 6. No abstract available.

PMID:
22309148
11.

Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 Receptors

Sromek AW, Si YG, Zhang T, George SR, Seeman P, Neumeyer JL.

ACS Med Chem Lett. 2011 Mar 10;2(3):189-194.

12.

Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.

Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL.

Bioorg Med Chem. 2011 May 1;19(9):2808-16. doi: 10.1016/j.bmc.2011.03.052. Epub 2011 Mar 26.

13.

Aminothiazolomorphinans with mixed κ and μ opioid activity.

Zhang T, Yan Z, Sromek A, Knapp BI, Scrimale T, Bidlack JM, Neumeyer JL.

J Med Chem. 2011 Mar 24;54(6):1903-13. doi: 10.1021/jm101542c. Epub 2011 Feb 25.

14.

Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic.

Balboni G, Salvadori S, Marczak ED, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Si YG, Neumeyer JL.

Eur J Med Chem. 2011 Feb;46(2):799-803. doi: 10.1016/j.ejmech.2010.12.001. Epub 2010 Dec 8.

15.

Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice.

SUN JF, WANG YH, LI FY, LU G, TAO YM, CHENG Y, CHEN J, XU XJ, CHI ZQ, NEUMEYER JL, ZHANG A, LIU JG.

Acta Pharmacol Sin. 2010 Dec;31(12):1547-52. doi: 10.1038/aps.2010.164. Epub 2010 Nov 22.

16.
17.

Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.

Balboni G, Salvadori S, Trapella C, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Neumeyer JL.

ACS Chem Neurosci. 2010 Feb 17;1(2):155-164.

18.

Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.

Fulton BS, Knapp BL, Bidlack JM, Neumeyer JL.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. doi: 10.1016/j.bmcl.2010.01.101. Epub 2010 Jan 25.

19.

Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.

Decker M, Si YG, Knapp BI, Bidlack JM, Neumeyer JL.

J Med Chem. 2010 Jan 14;53(1):402-18. doi: 10.1021/jm9013482.

20.

Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.

Decker M, Fulton BS, Zhang B, Knapp BI, Bidlack JM, Neumeyer JL.

J Med Chem. 2009 Dec 10;52(23):7389-96. doi: 10.1021/jm900379p.

21.

Arylbenzazepines are potent modulators for the delayed rectifier K+ channel: a potential mechanism for their neuroprotective effects.

Chen XQ, Zhang J, Neumeyer JL, Jin GZ, Hu GY, Zhang A, Zhen X.

PLoS One. 2009 Jun 5;4(6):e5811. doi: 10.1371/journal.pone.0005811.

22.

Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.

Wang YJ, Tao YM, Li FY, Wang YH, Xu XJ, Chen J, Cao YL, Chi ZQ, Neumeyer JL, Zhang A, Liu JG.

J Pharmacol Exp Ther. 2009 Apr;329(1):306-13. doi: 10.1124/jpet.108.142802. Epub 2009 Jan 9.

23.

Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines.

Si YG, Choi YK, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3. doi: 10.1016/j.bmcl.2008.11.025. Epub 2008 Nov 13.

PMID:
19058967
24.

Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.

Fulton BS, Knapp BI, Bidlack JM, Neumeyer JL.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4474-6. doi: 10.1016/j.bmcl.2008.07.054. Epub 2008 Jul 17.

25.

Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines.

Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3971-3. doi: 10.1016/j.bmcl.2008.06.016. Epub 2008 Jun 10.

PMID:
18585036
26.

In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.

Mathews JL, Fulton BS, Negus SS, Neumeyer JL, Bidlack JM.

Neurochem Res. 2008 Oct;33(10):2142-50. doi: 10.1007/s11064-008-9752-3. Epub 2008 Jun 5.

27.

Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity.

Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL.

J Med Chem. 2008 Feb 28;51(4):983-7. doi: 10.1021/jm701045j. Epub 2008 Feb 6.

PMID:
18251489
28.

Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test.

Reindl JD, Rowan K, Carey AN, Peng X, Neumeyer JL, McLaughlin JP.

Pharmacology. 2008;81(3):229-35. doi: 10.1159/000112867. Epub 2008 Jan 7.

PMID:
18176093
29.

Pharmacological characterization of the effects of dopamine D(1) agonists on eye blinking in rats.

Desai RI, Neumeyer JL, Bergman J, Paronis CA.

Behav Pharmacol. 2007 Dec;18(8):745-54.

PMID:
17989512
30.

R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands.

Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30. Epub 2007 May 23.

PMID:
17543523
31.

Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol.

Zhang A, Li F, Ding C, Yao Q, Knapp BI, Bidlack JM, Neumeyer JL.

J Med Chem. 2007 May 31;50(11):2747-51. Epub 2007 May 9.

PMID:
17488103
32.

Synthesis and radiopharmacological characterization of 2beta-carbo-2'-[18F]fluoroethoxy-3beta-(4-bromo-phenyl)tropane ([18F]MCL-322) as a PET radiotracer for imaging the dopamine transporter (DAT).

Wuest F, Berndt M, Strobel K, van den Hoff J, Peng X, Neumeyer JL, Bergmann R.

Bioorg Med Chem. 2007 Jul 1;15(13):4511-9. Epub 2007 Apr 19.

PMID:
17467995
33.

In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.

Peng X, Knapp BI, Bidlack JM, Neumeyer JL.

Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.

34.
35.

Kappa receptor bivalent ligands.

Peng X, Neumeyer JL.

Curr Top Med Chem. 2007;7(4):363-73. Review.

PMID:
17305578
36.

High-affinity carbamate analogues of morphinan at opioid receptors.

Peng X, Knapp BI, Bidlack JM, Neumeyer JL.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.

37.

Advances in development of dopaminergic aporphinoids.

Zhang A, Zhang Y, Branfman AR, Baldessarini RJ, Neumeyer JL.

J Med Chem. 2007 Jan 25;50(2):171-81. Review. No abstract available.

PMID:
17228858
38.

Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.

Zhang A, Neumeyer JL, Baldessarini RJ.

Chem Rev. 2007 Jan;107(1):274-302. Review. No abstract available.

PMID:
17212477
39.

Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys.

Desai RI, Neumeyer JL, Paronis CA, Nguyen P, Bergman J.

Eur J Pharmacol. 2007 Mar 8;558(1-3):98-106. Epub 2006 Dec 1. Erratum in: Eur J Pharmacol. 2007 Dec 1;575(1-3):187.

40.

New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.

Neumeyer JL, Peng X, Knapp BI, Bidlack JM, Lazarus LH, Salvadori S, Trapella C, Balboni G.

J Med Chem. 2006 Sep 7;49(18):5640-3.

41.
42.

Synthesis and dopamine receptor binding of sulfur-containing aporphines.

Tóth M, Berényi S, Csutorás C, Kula NS, Zhang K, Baldessarini RJ, Neumeyer JL.

Bioorg Med Chem. 2006 Mar 15;14(6):1918-23. Epub 2005 Nov 15.

PMID:
16290940
43.

Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.

Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, Bidlack JM.

J Pharmacol Exp Ther. 2005 Nov;315(2):821-7. Epub 2005 Aug 2.

PMID:
16076937
44.

Synthesis of 2-fluoro-11-hydroxy-N-propylnoraporphine: a potential dopamine D2 agonist.

Zhang A, Csutoras C, Zong R, Neumeyer JL.

Org Lett. 2005 Jul 21;7(15):3239-42.

PMID:
16018630
45.

A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey.

Finnema SJ, Seneca N, Farde L, Shchukin E, Sóvágó J, Gulyás B, Wikström HV, Innis RB, Neumeyer JL, Halldin C.

Nucl Med Biol. 2005 May;32(4):353-60.

PMID:
15878504
46.

Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents.

Peng X, Zhang A, Kula NS, Baldessarini RJ, Neumeyer JL.

Bioorg Med Chem Lett. 2004 Nov 15;14(22):5635-9.

PMID:
15482938
47.

Synthesis and neuropharmacological evaluation of R(-)-N-alkyl-11-hydroxynoraporphines and their esters.

Csutoras C, Zhang A, Zhang K, Kula NS, Baldessarini RJ, Neumeyer JL.

Bioorg Med Chem. 2004 Jul 1;12(13):3553-9.

PMID:
15186839
48.

An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to mu, delta, and kappa receptors.

Csutoras C, Zhang A, Bidlack JM, Neumeyer JL.

Bioorg Med Chem. 2004 May 15;12(10):2687-90.

PMID:
15110850
49.

2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.

Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, Neumeyer JL.

J Med Chem. 2004 Apr 8;47(8):1886-8.

PMID:
15055988
50.

Radiosynthesis of [18F] N-(3-Fluoropropyl)-2-beta-Carbomethoxy-3-beta-(4-Bromophenyl) Nortropane and the regional brain uptake in non human primate using PET.

Chaly T, Baldwin RM, Neumeyer JL, Hellman MJ, Dhawan V, Garg PK, Tamagnan G, Staley JK, Al-Tikriti MS, Hou Y, Zoghbi SS, Gu XH, Zong R, Eidelberg D.

Nucl Med Biol. 2004 Jan;31(1):125-31.

PMID:
14741577

Supplemental Content

Loading ...
Support Center